

Contents lists available at [ScienceDirect](#)

Diabetes Research and Clinical Practice

journal homepage: www.journals.elsevier.com/diabetes-research-and-clinical-practice

Corrigendum

Corrigendum to “Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy” [Diab. Res. Clin. Pract. 186 (2022) 109835]

Benjamin N. Rao ^{a,b}, Nicola Quinn ^{a,c}, Andrzej S. Januszewski ^a, Tunde Peto ^c, Laima Brazionis ^d, Nanda Aryal ^a, Rachel L. O’Connell ^a, Liping Li ^a, Paula Summanen ^e, Russell Scott ^f, Justin O’Day ^g, Anthony C. Keech ^{a,1}, Alicia J. Jenkins ^{a,c,d,*}, on behalf of the FIELD Study Group

^a NHMRC Clinical Trials Centre, The University of Sydney, Australia

^b Faculty of Medicine, Nursing and Health Sciences, Monash University, Australia

^c Centre for Public Health, Queens University, Belfast, Northern Ireland, United Kingdom

^d Department of Medicine, St. Vincent’s Hospital Campus, The University of Melbourne, Australia

^e Department of Ophthalmology, Helsinki University Hospital, University of Helsinki, Finland

^f Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand

^g Department of Ophthalmology, Royal Victorian Eye and Ear Hospital, The University of Melbourne, Australia

The authors regret an error occurred in Table 2, whereby a row was incorrectly labelled as “Female” rather than “Male”.

A correct version of [Table 2](#) is now reproduced below with the row

amended to “Male”. The odds ratios are correct for males.

The authors apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.diabres.2022.109835>.

* Corresponding author at: NHMRC Clinical Trials Centre, The University of Sydney, 92–94 Parramatta Rd, Camperdown 2050, Sydney, NSW, Australia.
E-mail address: Alicia.Jenkins@sydney.edu.au (A.J. Jenkins).

¹ Equal senior authors.

<https://doi.org/10.1016/j.diabres.2022.110234>

0168-8227/© 2022 Elsevier B.V. All rights reserved.

Table 2

	Unadjusted		Multivariable model	
	Odds Ratio (95% CI)	P-value	Odds Ratio (95% CI)	P-value
Treatment (Fenofibrate)	0.21 (0.08, 0.57)	0.002	0.13 (0.05, 0.38)	<0.001
Prior CVD	0.63 (0.19, 2.12)	0.456		
Prior MI	0.00 (0.00, 1)	0.978		
Prior stroke	2.84 (0.64, 12.6)	0.170		
Prior angina	0.36 (0.05, 2.69)	0.319		
Prior PVD	0.72 (0.10, 5.41)	0.749		
Age (years)	0.97 (0.91, 1.02)	0.248		
Male	4.00 (1.37,11.6)	0.011	4.34 (1.32,14.3)	0.016
Systolic BP (mm Hg)	1.01 (0.99, 1.04)	0.261		
Diastolic BP (mm Hg)	1.02 (0.98, 1.07)	0.315		
Baseline BMI (kg/m ²)	1.00 (0.93, 1.07)	0.993		
Waist-Hip Ratio	15.2 (0.43, 537)	0.134		
Total cholesterol (mmol/L)	0.63 (0.35, 1.12)	0.114		
HDL-Cholesterol (mmol/L)	1.46 (0.38, 5.57)	0.584		
Triglycerides (mmol/L)	0.98 (0.63, 1.51)	0.911		
LDL-Cholesterol (mmol/L)	0.55 (0.30, 1.01)	0.054		
Baseline diabetic retinopathy presence	33.4 (7.87, 142)	<0.001	24.0 (5.53, 104)	<0.001
Mean arterial pressure (mmHg)	1.02 (0.98, 1.07)	0.235		
BMI (≥ 30 kg/m ²)	1.36 (0.63, 2.93)	0.435		
Waist circumference (cm), sex-specific [†]	1.18 (0.49, 2.81)	0.715		
Waist-hip ratio, sex- specific [‡]	2.66 (0.63, 11.4)	0.185		
Current smoker	1.63 (0.55, 4.81)	0.377		
HbA1c (%)	1.94 (1.52, 2.46)	<0.001	1.95 (1.43, 2.64)	<0.001
Diabetes duration (years)	1.11 (1.06, 1.16)	<0.001		

CVD, cardiovascular disease; MI, myocardial infarction; BMI, body mass index; BP, blood pressure; PVD, peripheral vascular disease. P values <0.05 are bolded.

[†] ≥ 102 cm for men, ≥ 88 cm for women.

[‡] ≥ 0.9 for men, ≥ 0.85 for women.